Investors Home Page


The JN Investor Relations team is committed to providing the individual shareholder with timely, transparent information on the business, organization, progress of the projects and performance.

This site provides current and present and potential investors with information that is pertinent to the investment and financial community, including share price and trade volumes. 

Assets & Stock: Nebraska Secretary of State: The assets of the corporation = $24.144 million in 2006-2007and during 2010 the assets increased to $125 million (unaudited) based on Building, Equipment, issued Patents, Sales and Vaccine stock of the corporation. 36,000 shares were on Jan 2011-2012 is $9,341 / share on private par  (12,000 shares issued).  The share selling price has been adjusted according to number shares issued under "C" corporation statue of the State of Nebraska.  Subsidiary company assets not included. 

Financial performance: JN corporation has been well funded by the private investors and through US govt. research grants and revenues generated by marketing third party products. There is limited deficiency in funds to complete the projects. However, qualified investors and venture capitalists are welcome to purchase our stock at private par. It is anticipated that our Meningitis vaccine will be in the international market in 2012 and in North American market in 2013-2014.

A commitment to Shareholders: “Jn-International Medical Corporation is committed to create significant value for its  shareholders, customers and partners through a sustainable business strategy balancing short-term and long-term growth potentials ” - Account statements are submitted to the investors electronically at every 4 months. IRS tax returns and Corporate publications can be requested by telephone or e-mail and will be mailed by FedEx. Our investors always thanking to our world-class researchers, state-of-the-art technologies and facility engineers and unrelenting focus on scientific excellence, JN is at the forefront of discovering and developing innovative ways to treat and prevent disease. 

Financial documents and investor-related materials are available for review. You may request financial statements material by contacting us by telephone or email.


At JN code of conduct reflects our corporate values. We hold ourselves to high standards of ethical behavior, We work hard to make sure that the integrity of this company remains a priority for employees, customers, and shareholders.






Cautionary statement regarding forward-looking statements: This page contains projections and other forward-looking statements that are not historical facts. Although the management of JN believes that these projections and forward-looking statements, and their underlying assumptions, are reasonable as of the date of publication, investors are cautioned that such projections, assumptions, intentions and forward-looking statements are subject to various risks and uncertainties and many of which are difficult to predict and generally beyond the control of JN that could cause actual results and developments to differ materially from those expressed or implied.

© 1998 -2012 Jeeri Neotech International, Inc. Oakland, Nebraska 68045, USA . BYLAWS TERMS OF USE LEGAL DISCLAIMER